Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ABTC-1701||ABTC||Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients||Adult CIRB - Early Phase Emphasis||Available to Open|
|ABTC-1804||ABTC||Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with Gliomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|CITN-14||CITN||A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|PED-CITN-03||Pediatric CITN||Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma||Pediatric CIRB||Available to Open|
|PED-CITN-01||Pediatric CITN||3CI Study: Childhood Cancer Combination Immunotherapy. Phase 1b and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers||Pediatric CIRB||Available to Open|
|PEPN1812||PEP-CTN||A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|PEPN1924||PEP-CTN||A Phase 2 Study of DS-8201A (NSC# 807708, IND# TBD) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma||Pediatric CIRB||Available to Open|
|AMC-107||AMC||A Phase 2 Trial of Ixazomib for Kaposi Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|